A phase I/II trial of Clevegen (FP-1305)

Trial Profile

A phase I/II trial of Clevegen (FP-1305)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs FP-1305 (Primary)
  • Indications Liver cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Feb 2018 New trial record
    • 01 Feb 2018 The trial protocol is currently under review by regulators with feedback anticipated in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top